FNY Managed Accounts’s PTC Therapeutics PTCT Stock Holding History

FNY Managed Accounts’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-110	Closed	-$2.75K	–	385
2016 Q1	$2.75K	Buy	110 +102	+1,275%	+$1.77K	﹤0.01%	270
2015 Q4	$620	Buy	+8	New	+$235	﹤0.01%	147

Other funds holding PTCT

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FNY Managed Accounts's PTCT Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in PTC Therapeutics (PTCT) in Q1 2018: 90 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #415 among its holdings.

148 funds tracked by Wall St. Rank hold PTCT as of Q1 2018.

FNY Managed Accounts held 90 shares of PTC Therapeutics worth $2K as of Q1 2018.
PTC Therapeutics was a new FNY Managed Accounts position in Q1 2018.
PTC Therapeutics made up ﹤0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #415 holding.
148 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.